Quantitative analysis of plasma DNA in anal cancer patients

Introduction The availability and non-invasiveness of circulating cell-free DNA (cfDNA) opens up new possibilities for real-time serial testing. The relationship between cfDNA concentration, clinical factors and suitability for monitoring was analyzed in patients with newly diagnosed anal squamous c...

Full description

Saved in:
Bibliographic Details
Published in:Contemporary oncology (Poznań, Poland) Poland), 2022-01, Vol.26 (2), p.128-132
Main Authors: Małusecka, Ewa, Giglok, Monika, Suwiński, Rafał, Tomasz Wojciech Rutkowski, Mazurek, Agnieszka Maria
Format: Article
Language:English
Subjects:
Anal cancer
Anus
Blood
Cancer therapies
Chemotherapy
circulating cell-free dna
Colorectal cancer
Immune system
Laboratories
Neutrophils
Oncology
Original Paper
Plasma
Quantitative analysis
Radiation therapy
radiochemotherapy
Research centers
Tumors
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Introduction The availability and non-invasiveness of circulating cell-free DNA (cfDNA) opens up new possibilities for real-time serial testing. The relationship between cfDNA concentration, clinical factors and suitability for monitoring was analyzed in patients with newly diagnosed anal squamous cell carcinoma (ASCC). Material and methods Blood samples were collected at several points during and after treatment. Patients were homogeneously treated with chemoradiotherapy. Results The concentration of cfDNA strongly correlated with the tumor volume (r = 0.9, p = 0.00006) and number of neutrophils (r = 0.706, p = 0.0069). Monitoring of cfDNA levels during treatment showed an increase after initiation of therapy, a peak at the end of treatment with significantly higher values for advanced than in T1/T2 tumors, and a decrease (T3/T4) during follow-up. However, neither the concentration of cfDNA before treatment nor its changes correlated with the response to chemoradiotherapy. There was no association between baseline cfDNA levels and T, N, age and gender. Conclusions Substantial changes in plasma cfDNA content can be observed after chemoradiotherapy for ASCC. However, the small number of cases studied makes it difficult to assess the usefulness of the cfDNA test.
ISSN:1428-2526
1897-4309
DOI:10.5114/wo.2022.118132